← SynDRA
LINSIDOMINE
SynDRA canonical compound SYN0022864 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Mechanism of action | nitric oxide donor |
|---|
| Indication | erectile dysfunction |
|---|
| Disease area | urology |
|---|
All known targets
Mechanisms of action (all sources)
- nitric oxide donor
- Guanylyl cyclase activator
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ALDH1A1
- ALOX15
- TDP1
- SMN1
- RGS4
- POLB
- PLK1
- MAPT
- KDM4A
- HSD17B10
- HDAC6
- GMNN
- EHMT2
- CYP3A4
- CYP2D6
- CYP2C9
- CYP2C19
- CYP1A2
- BAZ2B
- ATAD5
- APEX1
- TRPC5
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Antihypertensive Agents
- Cardiovascular Agents
- Enzyme Inhibitors
- Hematologic Agents
- Nitric Oxide Donors
- Platelet Aggregation Inhibitors
- Vasodilator Agents
ATC classes
- C01D · VASODILATORS USED IN CARDIAC DISEASES
Cross-references
Synonyms
- linsidomine hydrochloride
- linsidomine HCl
- Linsidomina
- Sydnonimine-1
- SIN-1
- SIN1
- 3-Morpholinosydnone imine
- sin-1
- Linsidominum
- 3-Morpholinosydnoneimine
- CV-664
- 5O5U71P6VQ
- N-morpholino sydnonimine
- 3-Morpholino-sydnonimine
- SIN-1 morpholine
- 3-morpholinosydonimine
- RefChem:153577
- C01DX18
- DTXCID401510274
- 5-azanidyl-3-(morpholin-4-yl)-1,2,3lambda5-oxadiazol-3-ylium
- 3-MORPHOLINOSYDNONIMINE
- Linsidomine [INN]
- Linsidomine (INN)
- (3-Morpholino-1,2,3-oxadiazol-3-ium-5-yl)amide
- Linsidominum [Latin]
- Linsidomina [Spanish]
- 3-Morpholinosydnonimine-1
- UNII-5O5U71P6VQ
- Lopac-M-184
- LINSIDOMINE [WHO-DD]
- SCHEMBL160502
- orb1696451
- SCHEMBL29417895
- BDBM83470
- cid_9859122
- CHEBI:136004
- FKDHHVKWGRFRTG-UHFFFAOYSA-N
- AKOS005252588
Look up LINSIDOMINE in the interactive SynDRA portal →